iJOY Lio SS40000: Three-Tank Design E-Cigarette Review and Analysis

Jan.14.2025
iJOY Lio SS40000: Three-Tank Design E-Cigarette Review and Analysis
iJOY launches innovative three-tank e-cigarette, iJOY Lio SS40000, with adjustable ice and sweetness levels in the US market.

Special announcement:

This article is for internal industry communication only and does not make any recommendations for brands or products.

The images presented in this article are only used to depict facts and are not intended as advertisements for any products.

This article prohibits minors from accessing it.


 

iJOY recently launched a new e-cigarette model called the iJOY Lio SS40000, featuring a triple-pod design that allows for adjustable cooling and sweetness levels. The product has already hit the market in the United States.

 

iJOY Lio SS40000: Three-Tank Design E-Cigarette Review and Analysis
iJOY Lio SS40000 | Image source: worldvapeusa

 

Specifically, the product specifications of iJOY Lio SS40000 are as shown in the table below.

iJOY Lio SS40000: Three-Tank Design E-Cigarette Review and Analysis
iJOY Lio SS40000 Product Information | Design: Two to Supreme

 

The main feature of the iJOY Lio SS40000 e-cigarette is its three-pod system design. According to the manufacturer's website, the product includes a total of four ice levels and three sweetness options, allowing users to adjust both independently using two dedicated buttons.

 

In addition, the iJOY Lio SS40000 also features a 3D curved side screen, which can display battery level, e-liquid remaining amount, and monitor information such as ice level and sweetness level.

 

In December, Shenzhen Donghaoxing Technology Co., Ltd.'s e-cigarette brand Artery Vapor also launched a three-pod design e-cigarette, the Artery CL6 Sweet & Ice Control 50K, in the US market. This product also allows for adjusting the level of sweetness and ice. However, compared to the iJOY Lio SS40000, the Artery CL6 Sweet & Ice Control 50K has advantages in terms of the number of puffs and e-liquid capacity. (For more details, please refer to the article "Product | Three-pod design disposable e-cigarette launches in the US, offering adjustable ice and sweetness levels").

 

In the first half of 2024, iJoy has launched the e-cigarette iJoy Bar SD40000 in the United States, which has a capacity of 40,000 puffs. This product is among the first batch of e-cigarettes in the U.S. market to have a puff capacity of 40,000. Up to now, the performance of iJoy's e-cigarette products in terms of puff capacity has not seen any new breakthroughs. (For more details, please refer to "Product | iJoy launches 40,000 puff disposable e-cigarette in the U.S. with support for AI voice control")

 

The iJOY Lio SS40000 has landed on e-cigarette distributor websites such as vapesourcing, midwestgoods, and worldvapeusa, but is currently not available on the official iJOY website.

 


2Firsts will continue to monitor the performance and market trends of global e-cigarette products, providing the public with accurate and authoritative industry information.

 

2FIRSTS is a product column dedicated to providing readers with the latest information on new products in the tobacco industry. In order to collect and share first-hand information from the industry more broadly, 2FIRSTS welcomes readers to submit articles and share the latest products in the e-cigarette field with us.

 

If you have any unique insights or information, please feel free to contact us at info@2firsts.com at any time.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
Malaysia Withdraws Appeal Against Liquid Nicotine Ruling as Vape Regulation Framework Enters New Phase
Malaysia Withdraws Appeal Against Liquid Nicotine Ruling as Vape Regulation Framework Enters New Phase
Malaysia’s government has withdrawn its appeal against a High Court ruling concerning the regulatory status of liquid nicotine used in vape and e-cigarette products, according to reports by New Straits Times, Free Malaysia Today and CodeBlue on August 18, 2026. The Kuala Lumpur High Court ruled on May 15 that the government’s decision to remove liquid nicotine from the scheduled poisons list under the Poisons Act 1952 was irrational and made without proper consultation with the Poisons Board. The withdrawal ends the government’s appeal process, while the future regulatory framework for nicotine vape products remains under discussion.
Aug.21
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
Chinese authorities have disclosed the country’s first reported criminal case involving counterfeit vapes marketed as “medical nebulizers” and “zero-nicotine” products. Authorities determined that the products involved were counterfeit vapes and pursued criminal charges for producing and selling counterfeit goods. According to the report, the case resulted in the seizure of 347,000 counterfeit vape pods and 53,700 vape devices, with physical goods valued at 22.13 million yuan.
Aug.04
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
Science | International Experts Propose a New Smoking Cessation Pathway, Citing Higher Quit Rates With E-Cigarettes Than Nicotine Replacement Therapy
A new expert paper in JAMA urges U.S. clinicians to include nicotine e-cigarettes in smoking-cessation discussions, citing higher quit rates than nicotine replacement therapy. It also stresses that products must deliver enough nicotine to replace cigarettes, dual use should be brief, and complete switching is the goal. 2Firsts argues the recommendations matter beyond clinics: public-health professionals should reassess relative risk, regulators should preserve sufficient product appeal for adult smokers, and manufacturers should focus on helping users quit cigarettes more sustainably.
SCIENCE
Aug.03 by 2Firsts Perspectives